We keep our shareholders and investors informed about all important events. We invite you to read our current reports.

Current reports

22/2023

06.09.2023 17:09

Subject matter: Mabion enters into an agreement for the manufacture and delivery of a direct packaging leakage check and optical inspection line to the Company’s manufacturing facility

21/2023

18.08.2023 17:17

Registration of amendments to the Company’s Articles of Association

20/2023

31.07.2023 21:06

Information update on the loan agreement with the European Bank for Reconstruction and Development

19/2023

11.07.2023 14:47

Conclusion of an agreement for the supply of bioreactor set to the Company’s manufacturing facility

18/2023

13.06.2023 17:41

List of shareholders holding at least 5% of the votes at the Ordinary General Meeting of the Company after the meeting resumed on 13 June 2023.

List of shareholders holding at least 5% of the number of votes at the Ordinary General Meeting of Mabion S.A. on 7 June 2023 until the adjournment

17/2023

13.06.2023 17:34

Contents of resolutions put to the vote at the Ordinary General Meeting of Mabion S.A. after the meeting resumed on 13 June 2023

Contents of the resolutions put to the vote at the general meeting of Mabion S.A. held on 13 June 2023

16/2023

07.06.2023 18:42

List of shareholders holding at least 5% of the votes at the Ordinary General Meeting of the Company on 7 June 2023 until the adjournment

List of shareholders holding at least 5% of the number of votes at the Ordinary General Meeting of Mabion S.A. on 7 June 2023 until the adjournment

15/2023

07.06.2023 18:40

Appointment of Members of the Supervisory Board for the 3rd joint term of office

David John James – biogram

Józef Banach – biogram

Robert Koński – biogram

Sławomir Kościak – biogram

Wojciech Wośko – biogram

Zofia Szewczuk – biogram

14/2023

07.06.2023 18:38

Adjournment of the Ordinary General Meeting of Mabion S.A. and content of resolutions adopted until the adjournment

Contents of the resolutions of ordinary general meeting of Mabion S.A. of 7 June 2023

Remuneration policy for members of the management board and supervisory board of Mabion S.A. with its registered office in Konstantynów Łódzki

13/2023

31.05.2023 16:11

Submission of nominations for Members of the Supervisory Board

Robert Koński – biogram

Józef Banach – biogram

Zofia Szewczuk – biogram

Sławomir Kościak – biogram

David John James – biogram

12/2023

24.05.2023 12:41

Mabion receives as a notice of candidacy for a Member of the Company’s Supervisory Board

11/2023

22.05.2023 17:26

Conclusion of an annex to the agreement for the supply of bioreactors to the Company’s manufacturing facility

10/2023

22.05.2023 08:52

The Company terminates its agreement with Parexel for the clinical trial of MabionCD20

9/2023

11.05.2023 19:08

Notice convening the Annual General Meeting of Mabion S.A. for 7 June 2023, together with draft resolutions

8/2023

26.04.2023 11:04

Decision to close the patent procedures for MabionMS

7/2023

18.04.2023 05:18

Mabion S.A. adopts the Company Strategy for 2023–2027 and discloses delayed confidential information on the adoption of the strategy’s initial framework assumptions

Company Strategy for 2023–2027

6/2023

14.04.2023 20:13

Change of publication date of the annual report for 2022

5/2023

06.04.2023 11:33

Mabion signs annex with Novavax, Inc. for the manufacture of COVID-19 vaccine antigen, Omicron variant

4/2023

09.02.2023 08:12

Extension of cooperation with Novavax, Inc.

3/2023

06.02.2023 15:40

Termination of non-binding agreement with Polski Fundusz Rozwoju S.A.

2/2023

06.02.2023 15:21

Mabion signs a loan agreement for USD 15,000,000 with the European Bank for Reconstruction and Development

1/2023

24.01.2023 18:47

Deadlines for publication of periodic reports in the financial year 2023

36/2022

13.12.2022 14:31

KDPW’s statement on the assimilation of the Company’s S series ordinary bearer shares

35/2022

12.12.2022 12:43

Admission and introduction of the Company’s S series ordinary bearer shares to stock exchange trading

34/2022

23.11.2022 16:23

Extension of cooperation with Novavax, Inc.

33/2022

26.10.2022 22:21

The Company terminates the co-financing agreement for the project “Expansion of the Research and Development Centre of Mabion S.A. – research on a new generation of medicines”

32/2022

18.10.2022 15:55

Credit Committee of the European Bank for Reconstruction and Development approves financing for the Company

31/2022

22.09.2022 23:40

Broadening and extension of cooperation with Novavax, Inc. – Omicron variant

30/2022

19.09.2022 18:12

Change of the publication date of the first half of 2022 report

29/2022

30.08.2022 14:32

Allotment of shares and increase of the Company’s share capital as part of a conditional share capital increase

28/2022

24.08.2022 16:26

Statement of the Central Securities Depository of Poland on the registration of the Company’s S series shares

27/2022

08.08.2022 14:09

Summary of the subscription of the Company’s S series ordinary bearer shares carried out as part of the Incentive Scheme for 2021

26/2022

02.08.2022 18:18

Extension of cooperation with Novavax, Inc.

25/2022

30.07.2022 23:32

Extension of cooperation with Novavax

24/2022

18.07.2022 17:31

Registration of amendments to the Company’s Articles of Association.

Attachment

23/2022

14.07.2022 21:52

Receipt a notification of a change in the Company’s shareholding

Attachment

22/2022

12.07.2022 18:48

Conclusion of an annex to the loan agreement with Glatton Sp. z o.o.

21/2022

06.07.2022 10:04

Extension of cooperation with Novavax, Inc.

20/2022

21.06.2022 18:26

List of shareholders holding at least 5% of the votes at the Annual General Meeting of the Company on 21 June 2022.

Attachment

19/2022

21.06.2022 18:20

Contents of the resolutions of the Annual General Meeting of Mabion S.A. of 21 June 2022.

Attachment no. 1

Attachment no. 2

18/2022

08.06.2022 14:02

Extension of cooperation with Novavax

17/2022

28.05.2022 13:09

Extension of the scope of services under of manufacturing agreement with Novavax

16/2022

25.05.2022 19:47

Appointment of Members of the Management Board of Mabion S.A. for the second joint term of office

15/2022

15/2022

Notice of convening the Ordinary General Meeting of Mabion S.A. for 21 June 2022, together with draft resolutions

14/2022

11.05.2022 17:25

Change of dates of publication of interim reports in financil year 2022

13/2022

21.04.2022 23:38

KDPW’s statement on the assimilation of S series ordinary bearer shares of the Company

12/2022

20.04.2022 15:02

Admission and introduction of S series ordinary bearer shares of the Company to stock exchange trading

11/2022

19.04.2022 17:03

Registration of the Company as the manufacturer of the SARS-CoV-2 rS active substance in the Register of the Chief Pharmaceutical Inspectorate

10/2022

19.04.2022 14:07

Conclusion of an annex to the agreement on co-financing of the project entitled “Expansion of the Research and Development Centre of Mabion S.A. – research on the new generation of medicines”

09/2022

07.04.2022 20:08

Change of the publication date of the annual report for 2021

08/2022

02.03.2022 15:21

Notification of transactions in Mabion S.A. shares carried out by a person discharging managerial responsibilities

07/2022

24.02.2022 08:34

Decision to abandon further implementation of the research project on the development of MabionEGFR

06/2022

14.02.2022 15:02

Notification of transactions on Mabion S.A. shares performed by the person discharging managerial responsibilities.

05/2022

31.01.2022 17:27

Allotment of shares and increase of the Company’s share capital as part of a conditional share capital increase

04/2022

18.01.2022 17:21

Announcement of the National Depository of Securities (Krajowy Depozyt Papierów Wartościowych S.A.) concerning the registration of S series shares of the Company.

03/2022

18.01.2022 17:15

Mabion receives an additional order to provide analytical product quality control services under manufacturing agreement with Novavax, Inc.

02/2022

14.01.2022 08:22

Mabion receives an additional order for the production of cellular banks under the manufacturing agreement with Novavax, Inc.

01/2022

03.01.2022 16:08

Deadlines for publication of periodic reports in the financial year 2022.

70/2021

Notification of transactionson Mabion S.A.’s shares performed by a person discharging managerial responsibilities.

69/2021

Mabion obtains authorisation to conduct a bridging clinical trial of MabionCD20 in patients with reumatoid arthritis in Ukraine.

68/2021

Subscription summary for the Company’s S series ordinary bearer shares as part of the Incentive Scheme for 2020.

67/2021

An addendum to Current Report no. 26/2021 containing information on the completed subscription of U series shares issued by Mabion S.A.

66/2021

Mabion executes an annex to the borrowing agreement with Glatton Sp. z o.o.

65/2021

Resignation of a member of the Company’s Supervisory Board.

64/2021

Mabion enters into an agreement for the supply of four bioreactors to the Company’s manufacturing facility.

63/2021

Mabion enters into a quality agreement as part of its collaboration with Novavax, Inc.

62/2021

Termination of the cooperation agreement with Mylan Ireland Ltd.

61/2021

Notification of transactions in Mabion S.A. shares carried out by a person discharging managerial responsibilities.

60/2021

Notification of transactions in Mabion S.A. shares carried out by a person discharging managerial responsibilities.

59/2021

Notification of transactions in Mabion S.A. shares carried out by a person discharging managerial responsibilities.

58/2021

Notification of transactions in Mabion S.A. shares carried out by a person discharging managerial responsibilities.

57/2021

Mabion obtains authorisation to conduct a bridging clinical trial of MabionCD20 in patients with rheumatoid arthritis in Belgium.

56/2021

Change of the publication date of the Q3 2021 report.

55/2021

Notification of transactions in Mabion S.A. shares carried out by a person discharging managerial responsibilities.

54/2021

Mabion obtains authorisation to conduct a bridging clinical trial of MabionCD20 in patients with rheumatoid arthritis in Georgia.

53/2021

Mabion obtains authorisation to conduct a bridging clinical trial of MabionCD20 in patients with rheumatoid arthritis in Poland.

52/2021

Information on the execution of a commercial manufacturing agreement with Novavax, Inc. for the period of 2022-2025

51/2021

Registration of amendments to the Company’s Articles of Association.

50/2021

Change of the permit for business activity in the Łódź Special Economic Zone.

49/2021

Adoption of a joint work programme for the marketing authorisation of MabionCD20 in the European and US markets and elaboration of the final data and clinical trial scope for the registration application on the European market.

48/2021

Notification of transactions on Mabion S.A. shares performed by the person discharging managerial responsibilities.

47/2021

Receipt of the notice of the company’s shareholding

46/2021

Notification of transactions on Mabion S.A. shares performed by the person discharging managerial resposibilities.

45/2021

Update on the cooperation with Novavax Inc. on the COVID-19 vaccine programme.

44/2021

List of shareholders holding at least 5% of votes at the Ordinary General Meeting of the Company on June 22, 2021

43/2021

Appointment of a Member of the Company’s Supervisory Board. Appointment of a Member of the Company’s Supervisory Board

42/2021

The content of the resolutions of the Ordinary General Meeting of Mabion S.A. of 22 June 2021

41/2021

Receipt of the notice of change in the company’s shareholding.

40/2021

Notification of transactions on Mabion S.A. shares performed by the person discharging managerial responsibilities.

39/2021

Notification of transactions on Mabion S.A. shares performed by the person discharging managerial responsibilities.

38/2021

Receipt of a motion to supplement the agenda of the General Meeting and a candidacy for Member of the Supervisory Board

37/2021

Announcement on convening the Ordinary General Meeting of Mabion S.A. on June 22, 2021, alongside with draft resolutions

36/2021/K

Changes in the composition of the Company’s Management Board and Supervisory Board – correction of the numbering of the Current Report of 13 May 2021.

36/2021

Changes in the composition of the Company’s Management Board and Supervisory Board.

35/2021

Conclusion of an annex to the cooperation agreement with Mylan Ireland Ltd.

34/2021

Admission and introduction of ordinary bearer series U shares of the Company to stock exchange trading

33/2021

The conditional registration of series U shares of the Company with the National Depository for Securities

32/2021

Change of the publication date of the annual report for 2020

31/2021

Registration of the share capital increase and amendments to the Articles of Association

30/2021

Information on the performance of the first order under a framework agreement with Novavax, Inc.

29/2021

Registration of rights to series U shares of the Company in KDPW

28/2021

Admission and introduction of the rights to ordinary bearerseries U shares of the Company to exchange trading

27/2021

Conditional registration of rights to series U shares of theCompany in KDPW

26/2021

Information regarding the completed subscription for series Ushares issued by Mabion S.A.

25/2021

Cancellation of the Extraordinary General Meeting of MabionS.A. called for 22nd March 2021 and information on the review of the Company’s financing strategy

24/2021

Notifications about transactions on Mabion S.A. shares made by persons closely related to persons discharging managerial responsibilities in the Company

23/2021

Conclusion of contracts for the subscription for series U Mabion S.A. shares

22/2021

Notification of transactions on Mabion S.A. shares performed bythe person discharging managerial responsibilities

21/2021

Determination of the issue price of new Series U shares issued by MabionS.A. and the final number of series U shares to be offered by the Company

20/2021

Information on declarations of particular shareholderssubmitted in connection with the book-building process

19/2021

Mabion S.A. concludes a placement agreement and commences the book-building process for an offering by way of private subscription ofnew Series U ordinary bearer shares issued by Mabion S.A.

18/2021

Changes in the composition of the Management Board and Supervisory Board of the Company

17/2021

Notification of transactions on Mabion S.A. shares performed by the person discharging managerial responsibilities

16/2021

Conclusion of a preliminary agreement with Polski Fundusz Rozwoju S.A.

15/2021

Entering into a master service agreement with the first work order with Novavax Inc. for contract services related to the COVID-19 vaccine program

14/2021

List of shareholders holding at least 5% of votes at the Extraordinary General Meeting of the Company on February 23, 2021

13/2021

Changes in the composition of the Supervisory Board of the Company

12/2021

Content of resolutions of the Extraordinary General Meeting of Mabion S.A. of 23 February 2021

11/2021

Announcement on the convening of the Extraordinary General Meeting of Mabion S.A. of March 22, 2021 together with draft resolutions

10/2021

Issue of shares as part of the conditional increase of the Company’s share capital

9/2021

Registration of S series shares in KDPW

8/2021

Admission and introduction of S series shares to exchange trading

7/2021

Resignation of a Member of the Supervisory Board of the Company

6/2021

Receipt of nomination for member of the Supervisory Board of the Company

5/2021

Conclusion of a loan agreement with Twiti Investments Limited

4/2021

Announcement on convening the Extraordinary General Meeting ofMabion S.A. on February 23, 2021, alongside with draft resolutions

3/2021

Decision on commencing activities aimed at attracting astrategic investor for the Company and on two planned issues of the Company’s shares

2/2021

Assignment of Supervisory Board member to perform the duties of a member of the Management Board

1/2021

Dates for submission of periodical reports in the financial year of 2021

48/2020

Statement of the National Depository for Securities S.A. concerning: the conditional registration of series S shares with the National Depository for Securities

47/2020

The fifth summons to shareholders of Mabion S.A. for submitting the share documents in the Company’s registered office

46/2020

Conclusion of an annex to the loan agreement with Glatton Sp. z o.o.

45/2020

Update of information regarding the Company’s cooperation with Vaxine Pty Ltd. regarding a potential Covid-19 vaccine

44/2020

The fourth summons to shareholders of Mabion S.A. forsubmitting the share documents in the Company’s registered office

43/2020

The third summons to shareholders of Mabion S.A. for submitting the share documents in the Company’s registered office

42/2020

Updated information concerning the Company’s cooperation with Vaxine Pty Ltd. in scope of a potential Covid-19 vaccine

41/2020

Conclusion of an agreement with Parexel to conduct the final clinical trial before submitting a marketing authorisation application for MabionCD20 to the European Medicines Agency (EMA)

40/2020

Signing of the initial understanding in scope of cooperation covering research, development, and commercialisation of the antibodies of drug MabionCD20 in specific clinical indications concerning rare diseases.

39/2020

Receipt of a notification of change in the ownership of the Company’s shares

38/2020

The second summons to shareholders of Mabion S.A. for submitting the share documents in the Company’s registered office

37/2020

Signing of a Letter of Intent (LoI) on development work and production of the “IL-1R7 Antibody”, developed as a possible medication to treat Covid-19 infections.

36/2020

The first summons to shareholders of Mabion S.A. for submitting the share documents in the Company’s registered office

35/2020

Assignment of Supervisory Board member to replace a member of the Management Board

34/2020

Conclusion of Memorandum of Understanding on potential cooperation regarding a product that may be a vaccine for Covid-19 disease

33/2020

Resignation of a Member of the Management Board of the Company.

32/2020

Information regarding a meeting with the US Food and Drug Administration (FDA) concerning registration and marketing authorization for MabionCD20 drug on the territory of the USA.

31/2020

Conclusion of loan agreements from the main Shareholders of the Company

30/2020

Conclusion of loan agreement with Glatton Sp. z o. o.

29/2020

Information on initial assumptions regarding the renewed Marketing Authorization Application to be filed for MabionCD20

28/2020

Receipt of a written response from the European Medicines Agency as a part of the ‘Scientific Advice’ regarding the assumptions for the new registration process for MabionCD20

27/2020

Summary of the subscription of S series ordinary bearer shares of the Company carried out under the Incentive Scheme for 2019

26/2020

Satisfaction of the condition of the permit to conduct business activity in the Łódź Special Economic Zone.

25/2020

List of shareholders holding at least 5% of votes at the Ordinary General Meetingof the Company on June 15, 2020.

24/2020

Appointment of Supervisory Board members for the second term

24/2020

Attachment

23/2020

Content of the resolutions of the Ordinary General Meeting of Mabion S.A. of June 15, 2020

22/2020

Announcement on convening the Ordinary General Meeting of Mabion S.A. on June 15, 2020, along with draft resolutions

21/2020

Decision on the intention to issue U series ordinary bearer shares of the Company in order to increasethe share capital of Mabion S.A.

20/2020

Change of publication date of the annual report for 2019

19/2020

Information on the withdrawal of registration applications for MabionCD20 from the EMA

18/2020

Changes in the positions of Chairman and Deputy Chairman of the Supervisory Board

17/2020

Information on the impact of the COVID-19 spread on the Company’s activities

16/2020

Arrangements for financing the Company’s operations in light of the new regulatory strategy for registration of MabionCD20 in the EMA

15/2020

Change of regulatory strategy for the marketing authorisation of MabionCD20 in the EMA

14/2020

Resignation of a Member of the Supervisory Board of the Company and appointment of President of the Management Board of the Company

13/2020

Update on the registration procedure for the marketing authorisation of MabionCD20 by the European Medicines Agency

12/2020

Receipt of a summary of a BPD Type 3 meeting with the Food and Drug Administration (FDA) on the registration and marketing authorisation of MabionCD20 in the USA

11/2020

Receipt of the list of issues to be presented at the meeting of the Committee for Medicinal Products for Human Use to be held on 24-27 February 2020

10/2020

Change of the building permit for Mabion S.A. Science and Technology Centre for Advanced Medical Biotechnology in Konstantynów Łódzki.

9/2020

Change of the authorisation to conduct business activity in the Łódź Special Economic Zone

8/2020

Issue of shares under a conditional increase of the Company’s share capital

7/2020

Submitting answers to the questions as part of the registration procedure for MabionCD20 with the European Medicines Agency

6/2020

Registration of P and S series shares in KDPW

5/2020

Admission and introduction of P and S series shares to exchange trading

4/2020

Information regarding a Type 3 BPD meeting with the Food and Drug Administration (FDA) on the registration and marketing authorisation of MabionCD20 in the USA

3/2020

Declaration of the National Depository for Securities (KDPW) on conditional registration of P and S series shares in the KDPW

2/2020

Update information on the registration procedure for MabionCD20.

1/2020

Dates of publication of periodic reports in the financial year 2020.

38/2019

Receipt of the summary from the CHMP meeting regarding the registration procedure of the MabionCD20 drug.

37/2019

Update of information concerning the registration of drug MabionCD20 for marketing authorisation and disclosure of delayed confidential information.

36/2019

Obtaining approval on extension of the research project deadline from the National Centre for Research and Development.

35/2019

Registration of conditional increase of share capital and amendment to the Articles os Association.

34/2019

List of shareholders holding at least 5% of votes at the Extraordinary General Meeting of the Company on November 29, 2019.

33/2019

Summary of the subscription of the Company’s ordinary series S bearer shares carried out as part of the implementation of the Incentive Program for 2018.

32/2019

Contents of resolutions adopted by the Extraordinary Meeting of Shareholders of Mabion S.A. on 29 November 2019.

31/2019

Notifications about transactions on Mabion S.A. financial instruments made by a person discharging managerial responsibilities.

30/2019

Submission of answers to the Company’s Duplicate application for registration of MabionCD20 with the European Medicines Agency.

29/2019

Responses to round two of inquiries in scope of the registration procedure of MabionCD20 in the European Medicines Agency.

28/2019

Notice of convening the Extraordinary General Meeting of Mabion S.A. to be held on November 29, 2019, with draft resolutions attached.

27/2019

Appointment of BPD Type 3 meeting with the US Food and Drug Administration_FDA_concerning registration and marketing authorisation for the drug MabionCD20 within the territory of the United States.

26/2019

Agreement reached on the terms and conditions of and a decision made to conclude finance documentation with the European Investment Bank.

25/2019

Obtaining the GMP certificate for the Complex in Konstantynow Lodzki in the field of manufacturing a medicinal product.

24/2019

nformation on cooperation with Mylan.

23/2019

Registration of amendment to the Company’s Statute.

22/2019

Information from the European Medicines Agency on the assessment of the results of GMP inspection related to MabionCD20 production in the complex in Konstantynów Łódzki.

21/2019

Mabion S.A. obtains the GMP certificate for the complex in Konstantynów Łódzki for the production of the production of the active substance.

20/2019

Receipt of the second round of questions in the MabionCD20 registration procedure at the European Medicines Agency.

19/2019

Update of information on the composition of the Management Board of the Company.

18/2019/K

List of shareholders holding at least 5% of votes at the Ordinary General Meeting of the Company on June 18, 2019. – correction

18/2019

List of shareholders holding at least 5% of votes at the Ordinary General Meeting of the Company on June 18, 2019.

17/2019

Content of the resolutions of the Ordinary General Meeting of Mabion S.A. of June 18, 2019.

16/2019

Implementation of the last condition of permission for conducting the operation in the Lodz Special Economic Zone at the Scientific and Industrial Complex of Medical Biotechnology in Konstantynow Lodzki.

15/2019

The acceptance of the second registration application for MabionCD20 drug for assessment by the European Medicines Agency.

14/2019

Notice of convening the Ordinary General Meeting of Mabion S.A. to be held on June 18, 2019, with draft resolutions attached.

13/2019

The submission of the second registration application concerning MabionCD20 drug to the European Medicines Agency.

12/2019

Receipt of the notice of a change in ownership of the Company’s shares

11/2019

Resignation from the function of President of the Company’s Management Board.

10/2019/K

Submission of answers as part of the registration procedure for MabionCD20 at the European Medicines Agency – report correction.

10/2019

Submission of answers as part of the registration procedure for MabionCD20 at the European Medicines Agency.

9/2019

Change in the date of publication of the annual report for 2018.

8/2019

The update on development strategy of medicinal products.

7/2019

Conversion of ordinary registered series P shares into ordinary bearer shares.

6/2019

Information on the registration procedure for MabionCD20 in Turkey.

5/2019

Fulfilment of the condition stipulated in the permit for conducting economic activity in the area of the Lodz Special Economic Zone at the Medical and Biotechnology Complex in Konstantynow Lodzki.

4/2019

Notification about transactions on Mabion S.A. shares made by a person closely associated with a person fulfilling managing responsibilities

3/2019

Notification about transactions on Mabion S.A. shares made by a person closely associated with a person fulfilling managing responsibilities

2/2019

Dates of publication of periodic reports in the financial year 2019.

1/2019

Notifications about transactions on Mabion S.A. performed by person fulfilling managing responsibilities.

63/2018

Change in the Company’s Management Board.

62/2018

Notifications about transactions on Mabion S.A.